INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Grant or awardVerified data

Azoy Alexander reported RCUS

Chief Accounting Officer · Arcus Biosciences, Inc. · Common Stock

Side
A
Value
—
Shares
21.1K
Price
—
Executed
Jan 23, 2026
Disclosed
Jan 26, 2026
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Jan 23 executedJan 26, 2026 disclosed

RCUS · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
17/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+13 / 25

No reported dollar value · 113.6% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+4 / 15

    4 prior trades recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · RCUS

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    JJ
    Jarrett JenniferChief Operating Officer
    RCUSArcus Biosciences, Inc.
    Grant or award
    		A—
    126.0K sh
    		Jan 23, 2026Jan 26, 2026
    traded Jan 23, 2026
    		+3dSEC FORM 4

    Evidence

    13
    MR
    Markus RichardChief Medical Officer
    RCUSArcus Biosciences, Inc.
    Grant or award
    		A—
    24.0K sh
    		Jan 23, 2026Jan 26, 2026
    traded Jan 23, 2026
    		+3dSEC FORM 4

    Evidence

    5
    MR
    Markus RichardChief Medical Officer
    RCUSArcus Biosciences, Inc.
    Grant or award
    		A—
    96.0K sh
    		Jan 23, 2026Jan 26, 2026
    traded Jan 23, 2026
    		+3dSEC FORM 4

    Evidence

    9
    TC
    Tang Carolyn C.General Counsel
    RCUSArcus Biosciences, Inc.
    Grant or award
    		A—
    24.0K sh
    		Jan 23, 2026Jan 26, 2026
    traded Jan 23, 2026
    		+3dSEC FORM 4

    Evidence

    5
    TC
    Tang Carolyn C.General Counsel
    RCUSArcus Biosciences, Inc.
    Grant or award
    		A—
    96.0K sh
    		Jan 23, 2026Jan 26, 2026
    traded Jan 23, 2026
    		+3dSEC FORM 4

    Evidence

    5
    AA
    Azoy AlexanderChief Accounting Officer
    RCUSArcus Biosciences, Inc.
    Grant or award
    		A—
    14.1K sh
    		Jan 23, 2026Jan 26, 2026
    traded Jan 23, 2026
    		+3dSEC FORM 4

    Evidence

    13
    JJ
    Jarrett JenniferChief Operating Officer
    RCUSArcus Biosciences, Inc.
    Grant or award
    		A—
    31.0K sh
    		Jan 23, 2026Jan 26, 2026
    traded Jan 23, 2026
    		+3dSEC FORM 4

    Evidence

    9
    GC
    Goeltz II Robert C.Chief Financial Officer
    RCUSArcus Biosciences, Inc.
    Grant or award
    		A—
    96.0K sh
    		Jan 23, 2026Jan 26, 2026
    traded Jan 23, 2026
    		+3dSEC FORM 4

    Evidence

    17
    GC
    Goeltz II Robert C.Chief Financial Officer
    RCUSArcus Biosciences, Inc.
    Grant or award
    		A—
    24.0K sh
    		Jan 23, 2026Jan 26, 2026
    traded Jan 23, 2026
    		+3dSEC FORM 4

    Evidence

    22
    MR
    Markus RichardChief Medical Officer
    RCUSArcus Biosciences, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$111K
    5,052 sh
    		Dec 16, 2025Dec 18, 2025
    traded Dec 16, 2025
    		+2dSEC FORM 4

    Evidence

    18
    MR
    Markus RichardChief Medical Officer
    RCUSArcus Biosciences, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$100K
    4,494 sh
    		Dec 17, 2025Dec 18, 2025
    traded Dec 17, 2025
    		+1dSEC FORM 4

    Evidence

    22
    TC
    Tang Carolyn C.General Counsel
    RCUSArcus Biosciences, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$168K
    7,658 sh
    		Dec 16, 2025Dec 18, 2025
    traded Dec 16, 2025
    		+2dSEC FORM 4

    Evidence

    18
    TC
    Tang Carolyn C.General Counsel
    RCUSArcus Biosciences, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$151K
    6,810 sh
    		Dec 17, 2025Dec 18, 2025
    traded Dec 17, 2025
    		+1dSEC FORM 4

    Evidence

    18
    AA
    Azoy AlexanderChief Accounting Officer
    RCUSArcus Biosciences, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$52K
    2,376 sh
    		Dec 16, 2025Dec 18, 2025
    traded Dec 16, 2025
    		+2dSEC FORM 4

    Evidence

    15
    AA
    Azoy AlexanderChief Accounting Officer
    RCUSArcus Biosciences, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$47K
    2,113 sh
    		Dec 17, 2025Dec 18, 2025
    traded Dec 17, 2025
    		+1dSEC FORM 4

    Evidence

    18
    AA
    Azoy AlexanderChief Accounting Officer
    RCUSArcus Biosciences, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$97K
    4,343 sh
    		Dec 18, 2025Dec 18, 2025
    traded Dec 18, 2025
    		+0dSEC FORM 4

    Evidence

    13
    AA
    Azoy AlexanderChief Accounting Officer
    RCUSArcus Biosciences, Inc.
    Option exercise · 10b5-1 plan
    		M—
    1,900 sh
    		Nov 26, 2025Dec 1, 2025
    traded Nov 26, 2025
    		+5dSEC FORM 4

    Evidence

    15
    AA
    Azoy AlexanderChief Accounting Officer
    RCUSArcus Biosciences, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$49K
    1,900 sh
    		Nov 26, 2025Dec 1, 2025
    traded Nov 26, 2025
    		+5dSEC FORM 4

    Evidence

    9
    AA
    Azoy AlexanderChief Accounting Officer
    RCUSArcus Biosciences, Inc.
    Option exercise · 10b5-1 plan
    		M$25K
    1,900 sh
    		Nov 26, 2025Dec 1, 2025
    traded Nov 26, 2025
    		+5dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001771961-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 23, 2026
    Published
    Jan 26, 2026
    Ingested by INSIDER
    Nov 5, 04:20 UTC
    Last re-read
    Nov 5, 04:20 UTC

    Extracted facts

    Filer
    Azoy Alexander
    Role
    Chief Accounting Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Arcus Biosciences, Inc.
    Ticker
    RCUS
    Shares
    21.1K
    Price per share
    $0
    Execution date (reported)
    Jan 23, 2026
    Owned after transaction
    39.6K shares
    Days from execution to publication
    3

    What this establishes

    Azoy Alexander filed this Form 4 reporting a grant or award of RCUS on Jan 23, 2026. It became public on Jan 26, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Accounting Officer
    Azoy Alexandercik:0001771961
    Issuer
    Arcus Biosciences, Inc.cik:0001724521

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.